Kyowa Hakko Kirin Emphasizes Efforts On Kidney Disease With DPP-4
This article was originally published in PharmAsia News
Kyowa Hakko Kirin President Nobuo Hanai announced July 27 at a financial results briefing in Tokyo that the company will continue to provide a wide range of products targeting chronic kidney disease, with focus on renal anemia drugs NESP and ESPO.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.